Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
In a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.
Authors
- Michael A. O’Donnell (ORCID: https://orcid.org/0000-0001-7202-6427)
- Kendrick Yim (ORCID: https://orcid.org/0000-0002-4111-0279)
- Seth Lerner
- Facundo Davaro (ORCID: https://orcid.org/0000-0003-4116-3343)
- Jeffrey Howard (ORCID: https://orcid.org/0000-0002-0196-3875)
- Elizabeth Dyer (ORCID: https://orcid.org/0000-0002-4124-7654)
- Ashish M. Kamat (ORCID: https://orcid.org/0000-0003-3546-9928)
- Stephen Harrington (ORCID: https://orcid.org/0000-0002-9975-0850)
- M. Roumiguié (ORCID: https://orcid.org/0000-0002-2412-146X)
- Yair Lotan (ORCID: https://orcid.org/0000-0001-5692-2723)
- Ian M. McElree (ORCID: https://orcid.org/0000-0001-9991-4301)
- Peter C. Black (ORCID: https://orcid.org/0000-0002-2919-7068)
- Jayanthi Raman (ORCID: https://orcid.org/0000-0002-1320-6177)
- Roger Li (ORCID: https://orcid.org/0000-0003-1274-7200)
- Gary D. Steinberg (ORCID: https://orcid.org/0000-0003-4469-0624)
- Jacob Taylor (ORCID: https://orcid.org/0000-0003-2190-7309)
- Anna J. Black (ORCID: https://orcid.org/0000-0002-4305-766X)
- Pratik Kanabur (ORCID: https://orcid.org/0000-0002-1102-5727)
- Wei Shen Tan (ORCID: https://orcid.org/0000-0002-6119-4043)
- Solomon L. Woldu (ORCID: https://orcid.org/0000-0003-3282-7670)
- Vignesh T. Packiam (ORCID: https://orcid.org/0000-0001-8397-7797)
- William J. Huang (ORCID: https://orcid.org/0000-0001-9048-4990)
- Drupad Annapureddy
- Mark A. Preston (ORCID: https://orcid.org/0000-0003-1010-8464)
Institutions
- University of Iowa (US)
- Brigham and Women's Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of British Columbia (CA)
- Baylor College of Medicine (US)
- Moffitt Cancer Center (US)
- NYU Langone Health (US)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Penn State Milton S. Hershey Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1111/bju.16509
- Citations
- 25
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 14.32
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Intuitive Surgical
- Les Laboratories Pierre Fabre
- Progenics Pharmaceuticals
- Incyte
- Veracyte
- UroGen Pharma
- Seagen
- Eisai
- Astellas Pharma
- Fidia Farmaceutici
- Medac
- National Institutes of Health
- University of Texas MD Anderson Cancer Center